In a report published Friday, Mizuho Securities USA analyst Peter Lawson initiated coverage on Epizyme EPZM with a Buy rating and $35.00 price target.
In the report, Mizuho Securities USA noted, “We are initiating coverage of shares of Epizyme with a Buy rating and a price target of $35. Epizyme is a pure-play on epigenetics, a gene regulatory system that can be exploited to target cancer cells. While the company's pipeline is early phase, valuation is supported by a series of significant biopharmaceutical partners, a series of 4Q14 Phase I readouts, and a platform and IP for further discovery.”
Epizyme closed on Thursday at $28.20.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in